Asparaginase erwinia chrysanthemi clinical trials
Also written Erwinase, Crisantaspase and Rylaze™.
How each study uses asparaginase erwinia chrysanthemi is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the asparaginase erwinia chrysanthemi studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Nov 2011 · Erwinaze · BLA 125359 (FDA, Purple Book)
- European Union
- 15 Sept 2023 · Enrylaze · EMEA/H/C/005917 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2000 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 18
St. Jude Children's Research Hospital (9) · Jazz Pharmaceuticals (3) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (2) · Children's Oncology Group (1) · Ashkan Emadi (1) · Baylor College of Medicine (1) · University of Washington (1)
Often tested with
Tested in the same studies.
Etoposide (9) · Cytarabine (8) · Methotrexate (7) · Dexamethasone (7) · Pegaspargase (7) · Cyclophosphamide (7) · Mercaptopurine (7) · Vincristine (7)
Studies
Open first, then newest update. How each study uses asparaginase erwinia chrysanthemi is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT07133997Written as Asparaginase Erwinia chrysanthemiHow we know
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06918431Written as Asparaginase Erwinia chrysanthemiHow we know
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingEarly Phase 1Baylor College of MedicineNCT07059975Written as Asparaginase Erwinia Chrysanthemi (recombinant)How we know
- Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) IActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT02553460Written as Asparaginase Erwinia ChrysanthemiHow we know
- Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaSuspendedPhase 2University of WashingtonNCT06738368Written as Asparaginase Erwinia chrysanthemiHow we know
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down SyndromeActive, not recruitingPhase 3Children's Oncology GroupNCT02521493Written as Asparaginase Erwinia chrysanthemiHow we know
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingPhase 2/3St. Jude Children's Research HospitalNCT03117751Written as Erwinase®How we know
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT03164057Written as Erwinia asparaginaseHow we know
- An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)CompletedPhase 2/3Jazz PharmaceuticalsNCT04145531Written as IV JZP-458How we know
- Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedPhase 3St. Jude Children's Research HospitalNCT00549848Written as Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, ThioguanineHow we know
- NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic LymphomaCompletedPhase 2St. Jude Children's Research HospitalNCT01451515Written as Erwinia asparaginaseHow we know
- A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase TherapyCompletedPhase 2Jazz PharmaceuticalsNCT01643408Written as asparaginase Erwinia chrysanthemiHow we know
- Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedPhase 3St. Jude Children's Research HospitalNCT00137111Written as Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginaseHow we know
- Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)TerminatedPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT00928200Written as ErwinaseHow we know
- Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic MalignanciesWithdrawnPhase 2M.D. Anderson Cancer CenterNCT02718755Written as ErwinaseHow we know
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)CompletedPhase 1Ashkan EmadiNCT02283190Written as ErwinaseHow we know
- Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 2St. Jude Children's Research HospitalNCT00186875Written as L-asparaginase, erwinia asparaginaseHow we know
- Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins LymphomaCompletedPhase 1St. Jude Children's Research HospitalNCT00693602Written as ErwinaseHow we know
- An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)WithdrawnPhase 2Jazz PharmaceuticalsNCT02150928Written as Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)How we know
- Erwinase Study in Patients With Acute Lymphoblastic LeukemiaCompletedNot applicableM.D. Anderson Cancer CenterNCT00506597Written as ErwinaseHow we know
See all 21 studies that test asparaginase erwinia chrysanthemi →
Given beside what is tested · 14 — asparaginase erwinia chrysanthemi is usual care or a partner of the new treatment
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Asparaginase Erwinia chrysanthemiHow we know
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT04546399Written as Asparaginase Erwinia chrysanthemiHow we know
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Asparaginase Erwinia chrysanthemiHow we know
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingPhase 3Martin SchrappeNCT03643276Written as ErwinaseHow we know
- Ma-Spore ALL 2020 StudyRecruitingPhase 2National University Hospital, SingaporeNCT06336395Written as ErwinaseHow we know
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesActive, not recruitingPhase 1Andrew E. Place, MDNCT05292664Written as Erwinia asparaginaseHow we know
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03914625Written as Asparaginase Erwinia chrysanthemiHow we know
- Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxActive, not recruitingPhase 1/2St. Jude Children's Research HospitalNCT05192889Written as Erwinia asparaginaseHow we know
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT02981628Written as Asparaginase Erwinia chrysanthemiHow we know
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as Erwinia asparaginaseHow we know
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedPhase 2Incyte CorporationNCT02723994Written as Asparaginase Erwinia ChrysanthemiHow we know
- Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaTerminatedPhase 2SanofiNCT03860844Written as L - Asparaginase (Erwinase)How we know
- AflacLL1901 (CHOA-AML)TerminatedPhase 2Emory UniversityNCT04326439Written as ErwinaseHow we know
- Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesTerminatedPhase 2St. Jude Children's Research HospitalNCT02419755Written as Erwinia L-AsparaginaseHow we know
As the comparator · 1 — what is tested is compared with asparaginase erwinia chrysanthemi
Codes
What other systems call asparaginase erwinia chrysanthemi · ClinicalTrials.gg INT001667
- MeSH (NLM) C000718243asparaginase erwinia chrysanthemiConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D733ET3F9OASPARAGINASE ERWINIA CHRYSANTHEMIConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64260Asparaginase Erwinia chrysanthemiOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718243 | asparaginase erwinia chrysanthemi | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D733ET3F9O | ASPARAGINASE ERWINIA CHRYSANTHEMI | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64260 | Asparaginase Erwinia chrysanthemi | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.